Novartis Bolsters I-O Discovery Pipeline With Surface Oncology Deal
This article was originally published in Scrip
Novartis AG has made a new addition to its ever growing immuno-oncology portfolio, this time licensing four pre-clinical programs from Cambridge, Massachusetts-based biotech Surface Oncology, in a deal worth more than $170m.
You may also be interested in...
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.
Only two drug developers launched offerings in April and the average 2018 IPO return was just 9% – half the first quarter average – at the end of last month. Unity's May 1 offering was the 17th biopharma IPO this year.